Effective treatment options for neurological conditions such as stroke and spinal cord injury are limited due to the reduced capacity of the neural tissue to regenerate. Novel cellular, pharmacological and neuromodulation therapies often target the restoration of function by promoting enhanced plasticity of the neural tissue. Nonetheless, aberrant plasticity may arise from such interventions alone - if not paired with an appropriate rehabilitation regimen to guide regeneration in a functional manner. The pairing of rehabilitation with novel cellular, pharmacological and neuromodulation therapies shows promise for mitigating the sensorimotor deficits seen after neurological conditions. Moreover, there is an intense discussion about the dose and timing of rehabilitation.
This research topic aims to advance our understanding of the dose/timing of rehabilitation and the importance of combining novel regenerative treatments with targeted rehabilitation. These aspects are ideally explored both in the preclinical and clinical fields. The study of rehabilitation dose/timing is ideally studied in animal models because it is possible to control for rehabilitation by depriving a group of animals of it – which is not ethical in clinical settings. On the other hand, clinical studies provide definitive evidence of the efficacy of such combined interventions. In this topic, we aim to bring new commentaries and perspectives on the importance of the combination of novel regenerative, plasticity-promoting treatments with targeted rehabilitation. We also aim to bring original preclinical and clinical work about the dose and timing of rehabilitation and/or its association with novel cellular, pharmacological and neuromodulation therapies.
This topic also supports the translational research implementation pipeline. Thereby, discussions about methodological aspects related to the translation of novel findings on novel cellular, pharmacological and neuromodulation therapies from preclinical to clinical fields are also a focus of this topic. With the completion of this research topic, we will be able to better understand the effects of novel and promising treatments and technologies in experimental models and leverage the translation to the final end-user. Clinical research must feed on novel and experimental treatments, otherwise, the wheel will always spin at the same place (Figure). Ultimately, the integration of both preclinical and clinical research in this topic aims to facilitate the discovery and delivery of novel treatments to the final end-user.
Effective treatment options for neurological conditions such as stroke and spinal cord injury are limited due to the reduced capacity of the neural tissue to regenerate. Novel cellular, pharmacological and neuromodulation therapies often target the restoration of function by promoting enhanced plasticity of the neural tissue. Nonetheless, aberrant plasticity may arise from such interventions alone - if not paired with an appropriate rehabilitation regimen to guide regeneration in a functional manner. The pairing of rehabilitation with novel cellular, pharmacological and neuromodulation therapies shows promise for mitigating the sensorimotor deficits seen after neurological conditions. Moreover, there is an intense discussion about the dose and timing of rehabilitation.
This research topic aims to advance our understanding of the dose/timing of rehabilitation and the importance of combining novel regenerative treatments with targeted rehabilitation. These aspects are ideally explored both in the preclinical and clinical fields. The study of rehabilitation dose/timing is ideally studied in animal models because it is possible to control for rehabilitation by depriving a group of animals of it – which is not ethical in clinical settings. On the other hand, clinical studies provide definitive evidence of the efficacy of such combined interventions. In this topic, we aim to bring new commentaries and perspectives on the importance of the combination of novel regenerative, plasticity-promoting treatments with targeted rehabilitation. We also aim to bring original preclinical and clinical work about the dose and timing of rehabilitation and/or its association with novel cellular, pharmacological and neuromodulation therapies.
This topic also supports the translational research implementation pipeline. Thereby, discussions about methodological aspects related to the translation of novel findings on novel cellular, pharmacological and neuromodulation therapies from preclinical to clinical fields are also a focus of this topic. With the completion of this research topic, we will be able to better understand the effects of novel and promising treatments and technologies in experimental models and leverage the translation to the final end-user. Clinical research must feed on novel and experimental treatments, otherwise, the wheel will always spin at the same place (Figure). Ultimately, the integration of both preclinical and clinical research in this topic aims to facilitate the discovery and delivery of novel treatments to the final end-user.